XML 209 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenue $ 501,693 $ 429,485 $ 987,723 $ 931,554
Europe        
Disaggregation of Revenue [Line Items]        
Revenue 172,678 109,259 334,519 254,295
United States        
Disaggregation of Revenue [Line Items]        
Revenue 204,245 232,552 412,431 476,724
Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 42,248 37,864 101,953 97,788
Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 82,522 49,810 138,820 102,747
Total net product revenues        
Disaggregation of Revenue [Line Items]        
Revenue 486,670 419,032 954,439 908,075
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim        
Disaggregation of Revenue [Line Items]        
Revenue 458,542 386,740 876,302 820,117
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 166,704 104,319 315,576 245,170
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | United States        
Disaggregation of Revenue [Line Items]        
Revenue 169,411 197,171 324,474 378,842
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 42,248 37,864 101,953 97,788
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 80,179 47,386 134,299 98,317
Marketed by Genzyme | Aldurazyme        
Disaggregation of Revenue [Line Items]        
Revenue $ 28,128 $ 32,292 $ 78,137 $ 87,958